Beating Merck, Pfizer gets priority review as the first Prevnar follow-up heads to the FDA

Jason Mast

Editor

It won’t get quite the work-on-Thanksgiving welcome that the Covid-19 jab received, but another Pfizer vaccine is headed to the FDA, where it will receive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Beating Merck, Pfizer gets priority review as the first Prevnar follow-up heads to the FDA

Jason Mast

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Federal appeals court says Teva must delist Orange Book inhaler patents

Beat­ing Mer­ck, Pfiz­er gets pri­or­i­ty re­view as the first Pre­vnar fol­low-up heads to the FDA

Jason Mast

Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

Beating Merck, Pfizer gets priority review as the first Prevnar follow-up heads to the FDA

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Federal appeals court says Teva must delist Orange Book inhaler patents